Clinical Trial Update: A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating simmitinib in combination with irinotecan for advanced esophageal squamous cell carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Irinotecan (Irinotecan)
• Simmitinib (simmitinib)

Snippet

Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd | Conditions: Advanced Esophageal Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING